HTA38 When and How Does RWE Impact HTA Outcomes in Oncology? A Qualitative Evaluation of Case Studies to Identify Drivers of RWE Acceptance Today and in the Future

C Oswald,E Anastasaki,K Dunton,A Van Engen,B Liljas,Z Mbanya,D Parry,M Rosenlund,P Szawara

doi:10.1016/j.jval.2022.09.1498

HTA38 When and How Does RWE Impact HTA Outcomes in Oncology? A Qualitative Evaluation of Case Studies to Identify Drivers of RWE Acceptance Today and in the Future

C Oswald, E Anastasaki + Show 7 more

Open Access

https://doi.org/10.1016/j.jval.2022.09.1498

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Dec 1, 2022
License type: publisher-specific-oa

Affiliation: IQVIA (United Kingdom), Daiichi Sankyo (United Kingdom), IQVIA (United States), AstraZeneca (United Kingdom), Daiichi Sankyo (Germany)

#Real World Evidence #Health Technology Assessment + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Understand how different health technology assessment (HTA) bodies perceive and evaluate real world evidence (RWE) in oncology HTA submissions, and identify drivers of RWE acceptance today and in the future.

Full Text